CEA、CA125、CA199评估贝伐单抗靶向治疗联合XELOX辅助化疗方案对晚期结直肠癌的效果  

Evaluation effect of combined detection of CEA,CA125 and CA199 on the efficacy of bevacizumab targeted therapy combined with XELOX adjuvant chemotherapy on patients with advanced colorectal cancer

作　　者：王毅 赵红梅 郭鹏伟 郑波 崔海涛 WANG Yi;ZHAO Hongmei;GUO Pengwei(Department of General Surgery,Zhangjiakou First Hospital,Hebei,Zhangjiakou 075000,China;不详)

机构地区：[1]河北省张家口市第一医院普外科,075000 [2]河北省张家口市第五医院检验科

出　　处：《河北医药》2024年第8期1207-1209,1213,共4页Hebei Medical Journal

基　　金：河北省医学科学研究课题(编号:20221886)。

摘　　要：目的探讨癌胚抗原(CEA)、癌抗原125(CA125)、癌抗原199(CA199)联合检测评估贝伐单抗靶向治疗联合奥沙利铂和卡培他滨(XELOX)辅助化疗方案对晚期结直肠癌患者疗效及预后的效果。方法择取2019年3月至2020年3月就诊的晚期结直肠癌患者共计72例作研究对象,依照计算机随机分组模式归纳为对照组(36例,XELOX化疗)与试验组(36例,贝伐单抗+XELOX化疗),对比2组的临床疗效、短期生存率、血清指标水平、不良反应发生率。结果试验组与对照组的临床控制率分别为88.89%与66.67%,差异有统计学意义(P<0.05);试验组1年、2年生存率分别为91.67%与77.78%,均明显高于对照组(P<0.05);治疗前,2组血清CEA、CA125、CA199水平均无明显差异无统计学意义(P>0.05),治疗后,试验组上述指标水平均明显低于对照组(P<0.05);2组不良反应发生率均差异无统计学意义(P>0.05)。结论对晚期结直肠癌患者给予贝伐单抗+XELOX辅助化疗具有明显的临床疗效,帮助患者有效延长生存周期,降低血清指标水平,药效可靠,值得采纳。Objective To evaluate a combined detection of carcinoembryonic antigen(CEA),cancer antigen 125(CA125)and carbohydrate antigen 19-9(CA199)in assessing the efficacy of bevacizumab targeted therapy combined with XELOX(oxaliplatin plus capecitabine)adjuvant chemotherapy on patients with advanced colorectal cancer.Methods A total of 72 patients with advanced colorectal cancer admitted from March 2019 to March 2020 were selected as the subjects of this study,and they were randomly divided into control group(36 cases,XELOX chemotherapy)and experimental group(36 cases,bevacizumab+XELOX chemotherapy)according to the computer random grouping.The clinical efficacy,short-term survival rate,serum index levels and incidence of adverse events were compared between the two groups.Results The clinical control rate in the experimental group was significantly higher than that in the control group(88.89%vs 66.67%,P<0.05,respectively).The 1-year and 2-year survival rates in the experimental group were 91.67%and 77.78%,respectively,which were significantly higher than those of the control group(P<0.05).Before treatment,there were no significant differences in serum CEA,CA125 and CA199 levels between the two groups(P>0.05).After treatment,they were significantly lower in the experimental group than those of the control group(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Bevacizumab combined with XELOX adjuvant chemotherapy has an obvious clinical efficacy on patients with advanced colorectal cancer,which can effectively prolong the survival and reduce the levels of serum indicators.The efficacy is reliable and worthy of adoption.

关 键 词：晚期结直肠癌 XELOX化疗 贝伐单抗 CEA CA125 CA19 

分 类 号：R735.3[医药卫生—肿瘤]